OTCBB ALERTS

[r7315]

PLRS, moving on incredible news.

PLRS Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants

HAIFA, Israel--(Business Wire)--Pluristem Life Systems, Inc. (OTCBB: PLRS), a cell therapy company
dedicated to the commercialization of stem cell products, announces
promising final results of an animal model study which could benefit
100,000 blood cancer patients annually. PLX-I, the Company's
innovative adjuvant cell therapy product is based on Placenta Expanded
Mesenchymal cells. It intended to resolve the global shortfall of
matched tissue for blood cancer patients requiring bone marrow
transplantation by improving the engraftment of Umbilical Cord Blood
(UCB). The Pre-Clinical results document that adding Pluristem's PLX-I
to UCB stem cells during the Bone Marrow Transplant (BMT) human cell
engraftment in NOD SCID mice showed up to a 500% increased engraftment
after irradiation and Chemotropic treatment.

BMT traditionally treats patients whose bone marrow has been
damaged by chemotherapy, or certain genetic diseases that lead to
anemia, leukemia, lymphomas, autoimmune disease and other
blood-related disorders. Its effectiveness is severely limited because
of the lack of a matching donor or shortage of UCB stem cells
engrafted during the procedure. If additional animal studies and human
clinical trials prove equally successful as this first Pre-Clinical,
Pluristem's PLX-I product with 500% increased engraftment could lead
to more Bone Marrow Transplants (BMT) for these types of blood
cancers.

The animal studies were performed on immune-deficient NOD SCID
mice following systemic myeloablation of their bone marrow to simulate
the BMT clinical protocol. This in-vivo model is based on the known
ability of human Hematopoietic Stem Cells (HSC) to engraft in mouse
bone marrow and to simulate the recovery of the human's Hematological
system. 50,000-100,000 human UCB derived CD34+ cells (hUCB CD34+) were
injected into the tail vein of NOD-SCID mice along with 0.5*106 PLX I
cells. After periods of 28-32 days, mice were sacrificed and the
marrow was analyzed. Human cell engraftment was performed in both sub
lethally irradiated (350 Rad) and chemotherapy administrated (50 mg/kg
Busulfan) mice. FACS analysis of human CD45 positive cells in mice
bone marrow demonstrated an increscent of cell engraftment in part of
the experimental animals up to 5 folds compared to mice transplanted
with CD34+ cells only.

Mr. Zami Aberman, CEO, stated, "Co-transplantation of PLX-I cell
types may be a promising manipulation improving cord blood performance
during the bone marrow transplants in adults blood disorder. The
pre-clinical results suggest blood disorder treatment is being
improved by using MSC derived from placenta and expanded in
Pluristem's 3D bioreactor in combination with UCB derived HSC. We
strongly believe that PLX-I can change the clinical process now being
used to treat blood cancer and could eventually save millions of
lives."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company
that is developing and commercializing stem cell expansion technology
products for the treatment of severe blood disorders. The Company is
discovering and developing cell-based therapeutics that utilizes adult
stem cells expanded in a proprietary bioreactor mimicking different
naturally occurring physiological environments. Pluristem expects its
first products to be cell grafts that will provide an efficient and
superior alternative to the standard procedure of bone marrow
transplantation. Its first adult stem cell product targets a critical
global shortfall of matched tissue for bone marrow transplantation
since bone marrow transplantation is often the only cure for patients
suffering from leukemia, lymphoma, myeloma and many other
hematological diseases. The Company has made a strategic decision to
work only with adult stem cells since the practical use of embryonic
stem cells is severely restricted by various religious, ethical and
legal considerations.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include
statements: results of our animal model study could benefit 100,000
blood cancer patients annually; that PLX-1 is intended to resolve the
global shortfall of matched tissue for blood cancer patients requiring
bone marrow transplantation by improving the engraftment of Umbilical
Cord Blood (UCB); that if additional animal studies and human clinical
trials prove equally successful as this first Pre-Clinical,
Pluristem's PLX-I product with 500% increased engraftment could lead
to more Bone Marrow Transplants (BMT) for these types of blood
cancers; the pre-clinical results suggest blood disorder treatment is
being improved by using MSC derived from placenta and expanded in
Pluristem's 3D bioreactor in combination with UCB derived HSC; and we
believe that PLX-I can change the clinical process now being used to
treat blood cancer and could eventually save millions of lives.
Factors which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in
developing any products; that our technology may not be validated as
we progress further and our methods may not be accepted by the
scientific community; that pre-clinical trials results may not be able
to be successfully duplicated in clinical trials; that we are unable
to retain or attract key employees whose knowledge is essential to the
development of our products; that unforeseen scientific difficulties
develop with our process; that results in the laboratory do not
translate to equally good results in real surgical settings; that our
patents are not sufficient to protect essential aspects of our
technology; that competitors may invent better technology; that our
products may not work as well as hoped or worse, that our products may
harm recipients; and that we may not be able raise funds for
development or working capital when we require it. As well, our
products may never develop into useful products and even if they do,
they may not be approved for sale to the public. For further risk
factors see the Company's latest 10-KSB filed with the SEC.

Emerson Gerard Associates, Inc.
Media Contact
Jerry Jennings, 561-881-7318
[e-mail]

Copyright Business Wire 2006
16Oct06 11:31 GMT
Symbols:
us;PLRS
Source BW Business Wire
Categories:
MST/I/BTC MST/I/DRG MST/L/EN MST/R/AFR MST/R/IL TGT/BWB